Jump to content

Dasolampanel

From Wikipedia, the free encyclopedia

This is the current revision of this page, as edited by Michael7604 (talk | contribs) at 02:28, 9 January 2024 (change category from Chlorobenzenes to Chlorobenzene derivatives). The present address (URL) is a permanent link to this version.

(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)
Dasolampanel
Clinical data
ATC code
  • None
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC17H20ClN5O3
Molar mass377.83 g·mol−1
3D model (JSmol)

Dasolampanel (INN, USAN, code name NGX-426) is an orally bioavailable analog of tezampanel and thereby competitive antagonist of the AMPA and kainate receptors which was under development by Raptor Pharmaceuticals/Torrey Pines Therapeutics for the treatment of chronic pain conditions including neuropathic pain and migraine.[1] It was developed as a follow-on compound to tezampanel, as tezampanel is not bioavailable orally and must be administered by intravenous injection,[2][3] but ultimately neither drug was ever marketed.

See also

[edit]

References

[edit]
  1. ^ Stolerman IP (31 July 2010). Encyclopedia of Psychopharmacology. Springer Science & Business Media. pp. 514–. ISBN 978-3-540-68698-9.
  2. ^ Olesen J, Ramadan N (21 August 2008). Innovative Drug Development for Headache Disorders. Oxford University Press. pp. 188–. ISBN 978-0-19-955276-4.
  3. ^ Firestein GS, Budd R, Gabriel SE, O'Dell JR, McInnes IB (31 August 2012). Kelley's Textbook of Rheumatology: Expert Consult Premium Edition: Enhanced Online Features. Elsevier Health Sciences. pp. 1031–. ISBN 978-1-4557-3767-3.